Golidocitinib in Relapsed or Refractory Peripheral T-Cell Lymphoma
In a phase II trial (JACKPOT8 Part B) reported in The Lancet Oncology, Song et al found that the selective JAK1 tyrosine kinase inhibitor golidocitinib showed...
MRD Status and Outcomes With Obinutuzumab- and Rituximab-Based Treatment in Follicular Lymphoma
In an analysis from the phase III GALLIUM study reported in the Journal of Clinical Oncology, Pott et al identified measurable residual disease (MRD)...
FDA Grants Accelerated Approval to Tovorafenib for Patients With Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
On April 23, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the type II RAF inhibitor tovorafenib (Ojemda) for patients 6 months of age...
FDA Approves Lu-177 Dotatate for Pediatric Patients With GEP-NETs
On April 23, the U.S. Food and Drug Administration (FDA) approved lutetium Lu-177 dotatate (Lutathera) for pediatric patients aged 12 years and older...
Imaging Drug to Assist in Detection of Cancerous Tissue Following Lumpectomy Approved
Recently, the U.S. Food and Drug Administration (FDA) approved pegulicianine (Lumisight) for adult patients with breast cancer to assist in the intraoperative...
Susan Faye Dent: Cardio-Oncology Is a Growing Subspecialty, but Where Are the Oncologists?
Kelly Hewitt and Laura J. Esserman: Reframing DCIS as an Opportunity for Cancer Prevention
Garth Strohbehn, Allen Lichter, and Mark Ratain: Sotorasib, the Poster Child for Project Optimus
Kevin B. Knopf and Charles L. Bennett: Generic Drug Shortages and Essential Cancer Medicines
Stuart M. Lichtman: All Adult Oncologists Are Geriatric Oncologists
Sponsored Content
SPONSORED BY LILLY MEDICAL AFFAIRS
Targeting Rare, Actionable Alterations in Advanced Non–Small Cell Lung Cancer
Use of Integrative Medicine by Patients With Breast Cancer
Nearly three-quarters of patients with breast cancer (73%) reported using at least one type of complementary medicine after cancer diagnosis, while surveyed oncologists believed that less than half (43%) of patients were using these approaches during cancer care. These and other findings from a...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
New Web-Based Lesion Selection Tool May Improve Coordination, Performance, and Management of Biopsy Specimens
In a single-institution study reported in the Journal of Immunotherapy and Precision Oncology, Xu et al found that the use of a Web-based lesion selection tool (LST) developed by the research team improved consistency in lesion selection for sequential biopsy. In addition, the tool improved the...
Choice of First-Line Platinum Chemotherapy Does Not Significantly Impact Efficacy of Second-Line Immunotherapy in Advanced Urothelial Carcinoma
In a presentation of real-world data given during the 2021 ASCO Annual Meeting, Miron et al concluded that the choice of first-line platinum chemotherapy did not result in a significant difference in overall survival benefit among patients with advanced bladder cancer who were able to go on to...
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
Lay Health Worker–Led Intervention May Improve Care for Low-Income and Minority Patients With Cancer
In a study reported in JCO Oncology Practice, Manali I. Patel, MD, MPH, and colleagues found that a lay health worker–led intervention was associated with improved documentation of goals of care, increased clinical trial participation, and increased use of palliative care in a population of...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
